HB1244, titled the “Reducing Drug Prices for Seniors Act,” would amend the Medicare Part D prescription drug benefit so that certain beneficiary coinsurance amounts are calculated using a drug’s actual acquisition cost rather than its wholesale acquisition cost when the actual acquisition cost is lower. The bill applies to covered Part D drugs that are subject to coinsurance, not copayments, and it would take effect for plan years beginning on or after January 1, 2026. It also defines actual acquisition cost as the negotiated price under the plan, net of manufacturer price concessions, as reported in the plan’s detailed DIR reporting.
In practical terms, the bill is designed to lower out-of-pocket costs for Medicare beneficiaries, especially seniors, by tying cost-sharing more closely to the net price plans pay for drugs instead of a higher benchmark price. The legislation amends Section 1860D-2 of the Social Security Act and adds a conforming provision requiring Part D coverage to follow the new net-price-based coinsurance rule. It does not change the deductible or out-of-pocket threshold structure of Part D, but it changes how coinsurance is calculated within that benefit design.
Impact
The bill would directly amend federal Medicare law, specifically Section 1860D-2 of the Social Security Act, to require Part D plans and Medicare Advantage prescription drug plans to base certain coinsurance calculations on actual acquisition cost when that amount is below wholesale acquisition cost. This would affect plan sponsors, Medicare beneficiaries, and drug pricing/reporting practices by linking beneficiary cost-sharing to negotiated net prices and manufacturer concessions reported in DIR filings. The change would apply prospectively to plan years beginning on or after January 1, 2026.
Sentiment
Based on the bill title and the absence of recorded committee debate or votes in the provided materials, the measure appears to be framed positively as a consumer- and senior-focused drug cost reduction proposal. The sponsorship and naming suggest bipartisan or at least cross-party interest in lowering prescription drug costs for Medicare beneficiaries. However, because there are no transcripts or vote results included, there is no documented legislative sentiment beyond the bill’s stated purpose.
Contention
The main policy issue is the pricing benchmark used for Medicare Part D coinsurance. Supporters are likely to favor using actual acquisition cost because it more closely reflects the net price plans pay and could reduce beneficiary cost-sharing. Potential opponents or skeptics may question whether the change complicates plan administration, affects pricing transparency, or shifts costs within Part D rather than reducing them overall. The bill also excludes drugs covered under paragraphs (8) and (9), so any debate could focus on why those categories are treated differently and whether the new rule should apply more broadly.